JO
KZR

John Overdeck’s Kezar Life Sciences KZR Stock Holding History

John Overdeck’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,312
Closed -$71.2K – 4773
2025
Q4 		$71.2K Sell
11,312
-12,370
-52% -$72.1K ﹤0.01% 3891
2025
Q3 		$92.4K Sell
23,682
-1,201
-5% -$4.92K ﹤0.01% 3483
2025
Q2 		$114K Sell
24,883
-6,987
-22% -$30K ﹤0.01% 2985
2025
Q1 		$156K Sell
31,870
-30,113
-49% -$183K ﹤0.01% 2900
2024
Q4 		$417K Sell
61,983
-28,194
-31% -$210K ﹤0.01% 2615
2024
Q3 		$697K Sell
90,177
-24,641
-21% -$149K ﹤0.01% 2310
2024
Q2 		$689K Sell
114,818
-15,407
-12% -$117K ﹤0.01% 2203
2024
Q1 		$1.17M Buy
130,225
+8,600
+7% +$78.3K ﹤0.01% 1850
2023
Q4 		$1.15M Buy
121,625
+53,781
+79% +$473K ﹤0.01% 1993
2023
Q3 		$807K Sell
67,844
-9,860
-13% -$175K ﹤0.01% 2052
2023
Q2 		$1.9M Buy
77,704
+20,566
+36% +$535K ﹤0.01% 1464
2023
Q1 		$1.79M Buy
57,138
+54,387
+1,977% +$3.15M 0.01% 1455
2022
Q4 		$194K Sell
2,751
-5,734
-68% -$425K ﹤0.01% 2402
2022
Q3 		$731K Sell
8,485
-1,775
-17% -$172K ﹤0.01% 1599
2022
Q2 		$849K Sell
10,260
-42,317
-80% -$3.73M ﹤0.01% 1613
2022
Q1 		$8.74M Buy
52,577
+2,625
+5% +$377K 0.03% 660
2021
Q4 		$8.35M Buy
49,952
+33,722
+208% +$3.81M 0.02% 886
2021
Q3 		$1.4M Buy
16,230
+6,607
+69% +$437K ﹤0.01% 2307
2021
Q2 		$523K Sell
9,623
-9,112
-49% -$517K ﹤0.01% 3056
2021
Q1 		$1.12M Sell
18,735
-235
-1% -$13.7K ﹤0.01% 2207
2020
Q4 		$990K Sell
18,970
-3,317
-15% -$185K ﹤0.01% 2016
2020
Q3 		$1.08M Sell
22,287
-3,482
-14% -$167K ﹤0.01% 1700
2020
Q2 		$1.33M Buy
25,769
+14,261
+124% +$720K 0.01% 1338
2020
Q1 		$502K Buy
11,508
+2,642
+30% +$107K ﹤0.01% 1925
2019
Q4 		$356K Sell
8,866
-3,340
-27% -$103K ﹤0.01% 3058
2019
Q3 		$400K Buy
12,206
+8,994
+280% +$434K ﹤0.01% 2731
2019
Q2 		$248K Buy
3,212
+2,054
+177% +$319K ﹤0.01% 2968
2019
Q1 		$205K Buy
+1,158
New +$228K ﹤0.01% 2806

Other funds holding KZR

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

John Overdeck's KZR Position: Q1 2026 in Review

John Overdeck sold out of Kezar Life Sciences (KZR) in Q1 2026, closing a stake of 11,312 shares — an estimated $71.2K sold.

John Overdeck first reported a position in KZR in Q1 2019 and held it in 28 quarters. The position peaked at $8.74M in Q1 2022. 43 funds tracked by Wall St. Rank hold KZR as of Q1 2026.

  • John Overdeck reported no remaining Kezar Life Sciences position as of Q1 2026 after selling out during the quarter.
  • John Overdeck sold 11,312 Kezar Life Sciences shares in Q1 2026, an estimated $71.2K.
  • John Overdeck first reported a position in Kezar Life Sciences in Q1 2019 and held it in 28 quarters.
  • John Overdeck's Kezar Life Sciences position peaked at $8.74M in Q1 2022.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.